Vivo Bio Tech

Vivo Bio Tech Equity

The The Equity of Vivo Bio Tech (511509.BO) as of Oct 19, 2026 is 931.58 M INR. In the previous year, The Equity was 779.05 M INR — a change of 19.58% (higher).

Equity

931.58 MINR

YoY

19.58%

Last updated:

In 2026, Vivo Bio Tech's equity was 931.58 M INR, a 19.58% increase from the 779.05 M INR equity in the previous year.

The Vivo Bio Tech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
272.72 M INR
Jan 1, 2020
330.24 M INR
Jan 1, 2021
425.27 M INR
Jan 1, 2022
459.46 M INR
Jan 1, 2023
518.73 M INR
Jan 1, 2024
544.00 M INR
Jan 1, 2025
779.05 M INR
Jan 1, 2026
931.58 M INR
The Vivo Bio Tech Equity history
YEAREquityYoY
931.58 MINR+19.58%
779.05 MINR+43.21%
544.00 MINR+4.87%
518.73 MINR+12.90%
459.46 MINR+8.04%
425.27 MINR+28.78%
330.24 MINR+21.09%
272.72 MINR+41.25%
193.08 MINR+53.67%
125.64 MINR+24.87%
100.62 MINR+9.68%
91.74 MINR+7.61%
85.25 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vivo Bio Tech Stock analysis

What does Vivo Bio Tech do? Vivo Bio Tech Ltd, based in Hyderabad, India, provides drug development and discovery services to global pharmaceutical and biotech companies. The company specializes in in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic analyses, genotoxicity screening, and analytical services. It offers regulatory and non-regulatory IND-enabling preclinical development services, including customized in vivo drug metabolism and pharmacokinetics studies for rodent and non-rodent models. Additionally, Vivo Bio Tech develops syngeneic and xenograft models for oncology research to evaluate anti-cancer agents. Vivo Bio Tech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Vivo Bio Tech's Equity

Vivo Bio Tech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Vivo Bio Tech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Vivo Bio Tech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Vivo Bio Tech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Vivo Bio Tech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Vivo Bio Tech stock

The Equity of Vivo Bio Tech is 931.58 M INR in 2026.

The Equity of Vivo Bio Tech changed from 779.05 M INR to 931.58 M INR, representing a 19.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Vivo Bio Tech since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Vivo Bio Tech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Vivo Bio Tech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vivo Bio Tech